Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.
Life Sci
; 94(2): 115-21, 2014 Jan 17.
Article
em En
| MEDLINE
| ID: mdl-24269216
ABSTRACT
AIMS:
GPR40 is a free fatty acid receptor that regulates glucose-dependent insulin secretion at pancreatic ß-cells and glucagon-like peptide-1 (GLP-1), one of the major incretins, secretion at the endocrine cells of the gastrointestinal tract. We investigated the synergistic effect of AS2575959, a novel GPR40 agonist, in combination with sitagliptin, a major dipeptidyl peptidase-IV (DPP-IV) inhibitor, on glucose-dependent insulin secretion and GLP-1 secretion. In addition, we investigated the chronic effects of AS2575959 on whole-body glucose metabolism. MAINMETHODS:
We evaluated acute glucose metabolism on insulin and GLP-1 secretion using an oral glucose tolerance test (OGTT) as well as assessed the chronic glucose metabolism in diabetic ob/ob mice following the repeated administration of AS2575959. KEYFINDINGS:
We discovered the novel GPR40 agonist sodium [(3S)-6-({4'-[(3S)-3,4-dihydroxybutoxy]-2,2',6'-trimethyl[1,1'-biphenyl]-3-yl}methoxy)-3H-spiro[1-benzofuran-2,1'-cyclopropan]-3-yl]acetate (AS2575959) and found that the compound influenced glucose-dependent insulin secretion both in vitro pancreas ß-cell-derived cells and in vivo mice OGTT. Further, we observed a synergistic effect of AS2575959 and DPP-IV inhibitor on insulin secretion and plasma GLP-1 level. In addition, we discovered the improvement in glucose metabolism on repeated administration of AS2575959.SIGNIFICANCE:
To our knowledge, this study is the first to demonstrate the synergistic effect of a GPR40 agonist and DPP-IV inhibitor on the glucose-dependent insulin secretion and GLP-1 concentration increase. These findings suggest that GPR40 agonists may represent a promising therapeutic strategy for the treatment of type 2 diabetes mellitus, particularly when used in combination with DPP-IV inhibitors.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirazinas
/
Compostos de Espiro
/
Triazóis
/
Receptores Acoplados a Proteínas G
/
Inibidores da Dipeptidil Peptidase IV
/
Incretinas
/
Glucose
/
Hipoglicemiantes
/
Insulina
/
Acetatos
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article